DelveInsight Market Research Report
DelveInsight Market Research Report
Heart Failure Pipeline Insight, 2023
  • Published Date : Apr 2023

  • Pages : 300

  • Delivery Time : 72 Hours

  • Region : Global

Heart Failure Pipeline

DelveInsight’s, “Heart Failure Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Heart Failure pipeline landscape. It covers the pipeline drug profiles, including Heart Failure clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Heart Failure Pipeline: Understanding

Heart Failure: Overview

Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations. Heart failure is a pathological condition in which the heart is unable to pump enough blood to the rest of the body, because it is either unable to fill with a sufficient volume of blood or unable to generate sufficient force to pump out enough blood. Dysfunction of the pericardium, myocardium, endocardium, heart valves or great vessels alone or in combination is also associated with HF.

Heart failure can severely decrease the functional capacity of a patient and increase mortality risk. It is imperative to diagnose and effectively treat the disease to prevent recurrent hospitalizations, improve quality of life, and enhance patient outcomes. The treatment of heart failure requires a multifaceted approach involving patient education, optimal medical regimen to improve cardiac contractility, and prevention/limitation of exacerbations. The cardinal manifestations of HF are dyspnea and fatigue, which may limit exercise tolerance and fluid retention, which may lead to pulmonary and/or splanchnic congestion and/or peripheral edema. Heart failure, remains a stubborn problem and is now considered to be the greatest challenge in cardiovascular medicine and surgery.

“Heart Failure - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure pipeline landscape is provided which includes the disease overview and Heart Failure treatment guidelines. The assessment part of the report embraces, in depth Heart Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Heart Failure R&D. The therapies under development are focused on novel approaches to treat/improve Heart Failure.

Heart Failure Emerging Drugs Chapters

This segment of the Heart Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Heart Failure Emerging Drugs

Tirzepatide: Eli Lilly and Company

Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in phase 3 development for chronic weight management and heart failure with preserved ejection fraction (HFpEF).

Finerenone (BAY94-8862): Bayer

Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block the harmful effects of the overactivated mineralocorticoid receptor (MR) system. MR overactivation is a major driver of heart and kidney damage. Current steroidal MRAs on the market have proven to be effective in reducing cardiovascular mortality in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, they are often underutilized due to the incidence of hyperkalemia, renal dysfunction, and anti-androgenic / progestogenic side effects.

The initiation of the Phase III FINEARTS-HF study (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure) builds upon the robust Phase II studies ARTS-HF and ARTS-DN which investigated the efficacy and safety of finerenone in patients with heart failure and chronic kidney disease, respectively. Data from the Phase II study program ARTS were presented at ESC Congress 2015 in London.

CardiAMP Cell Therapy: BioCardia

CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively screen for cell therapeutic potency in order to improve patient outcomes. CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy, which the company believes improves the probability of success of the treatment: a pre-procedural diagnostic for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial delivery systems and more successful for enhancing cell retention.

Firibastat: Quantum Genomics

Firibastat is the first drug candidate in a new class of therapeutic agents called BAPAIs (Brain Aminopeptidase an Inhibitors). Firibastat is a prodrug that releases EC33, a specific and selective inhibitor of Aminopeptidase A in the brain, thereby preventing the production of angiotensin III in the brain. After collecting excellent data on animal efficacy and human safety in the Phase IIa study, Quantum Genomics announced the design of its Phase IIb study in heart failure last June 2018 with Firibastat. Firibastat currently is in Phase II for the Heart Failure.

HU 6: Rivus Pharmaceuticals

HU6 is a controlled metabolic accelerator (CMA) that provides a novel, measured approach to activating proton leak and mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat throughout the body.

Further product details are provided in the report……..

Heart Failure: Therapeutic Assessment

This segment of the report provides insights about the different Heart Failure drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Heart Failure

There are approx. 75+ key companies which are developing the therapies for Heart Failure. The companies which have their Heart Failure drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company


DelveInsight’s report covers around 90+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Product Type

​​Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Heart Failure Pipeline Development Activities

The Heart Failure pipeline report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart Failure therapeutic drugs key players involved in developing key drugs.

Heart Failure Pipeline Development Activities

The Heart Failure pipeline report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart Failure drugs.

Heart Failure Pipeline Report Insights

  • Heart Failure Pipeline Analysis
  • Heart Failure Therapeutic Assessment
  • Unmet Needs
  • Impact of Heart Failure Drugs

Heart Failure Pipeline Report Assessment

  • Heart Failure Pipeline Product Profiles
  • Heart Failure Therapeutic Assessment
  • Heart Failure Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Heart Failure drugs?
  • How many Heart Failure drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart Failure?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart Failure therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Heart Failure and their status?
  • What are the key designations that have been granted to the emerging drugs?


Executive Summary

Heart Failure : Overview

  • Introduction
  • Classification
  • Causes and Risk factors
  • Diagnosis
  • Etiology
  • Pathogenesis
  • Signs and Symptoms
  • Treatment

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
  • Assessment by Product Type
  • Assessment by Stage and Product Type

Heart Failure – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Tirzepatide: Eli Lilly and Company

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

HU 6: Rivus Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

HiCM 188: Help Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Heart Failure - Collaborations Assessment- Licensing / Partnering / Funding

Heart Failure - Unmet Needs

Heart Failure - Market Drivers and Barriers


List of Tables:

  • Table 1: Total Products for Heart Failure
  • Table 2: Late Stage Products
  • Table 3: Mid Stage Products
  • Table 4: Early Stage Products
  • Table 5: Pre-clinical & Discovery Stage Products
  • Table 6: Assessment by Product Type
  • Table 7: Assessment by Stage and Product Type
  • Table 8: Assessment by Route of Administration
  • Table 9: Assessment by Stage and Route of Administration
  • Table 10: Assessment by Molecule Type
  • Table 11: Assessment by Stage and Molecule Type
  • Table 12: Inactive Products

List of Figures:

  • Figure 1: Total Products for Heart Failure
  • Figure 2: Late Stage Products
  • Figure 3: Mid Stage Products
  • Figure 4: Early Stage Products
  • Figure 5: Preclinical and Discovery Stage Products
  • Figure 6: Assessment by Product Type
  • Figure 7: Assessment by Stage and Product Type
  • Figure 8: Assessment by Route of Administration
  • Figure 9: Assessment by Stage and Route of Administration
  • Figure 10: Assessment by Molecule Type
  • Figure 11: Assessment by Stage and Molecule Type
  • Figure 12: Inactive Products

List of Companies:

  • Zensun (Shanghai) Sci & Tech
    Windtree Therapeutics
    TreeFrog Therapeutics
    Torrent Pharmaceuticals
    Tenaya Therapeutics
    Tasly Pharmaceuticals
    Stealth BioTherapeutics
    SQ Innovation
    Shanghai Hongyitang Biopharmaceutical Technology
    Sana Biotechnology
    Salubris Biotherapeutics
    Rivus Pharmaceuticals
    Renova Therapeutics
    Regeneron Pharmaceuticals
    Quantum Genomics
    Procella Therapeutics
    Paradigm biopharmaceuticals
    Palatin Technologies
    Orizuru Therapeutics
    Olatec Therapeutics
    Novo Nordisk
    Mesoblast Inc.
    Merck & Co
    Lexicon Pharmaceuticals
    Janssen Research & Development
    Ionis Pharmaceuticals
    Intra-Cellular Therapies
    Imbria Pharmaceuticals
    Imara Inc
    Hyloris Pharmaceuticals
    Help Therapeutics
    HAYA Therapeutics
    GB Sciences
    Fujifilm Corporation
    Evotec SE
    Eli Lilly and Company
    Edgewise Therapeutics
    Chong Kun Dang
    Cardurion Pharmaceuticals
    Cardior Pharmaceuticals
    Cardiol Therapeutics
    Bristol-Myers Squibb
    Bristol Myers Squibb
    Boryung Pharmaceutical
    BlueRock Therapeutics
    Berlin Cures
    Asklepios Biopharmaceutical
    Antlia Biosciences
    Actelion Pharmaceuticals

Related Reports

Chronic Heart Failure - Market Insight, Epidemiology And Market Forecast - 2032

Chronic Heart Failure - Market Insight, Epidemiology And Market Forecast - 2032

Acute Heart failure Market Insight, Epidemiology And Market Forecast - 2032

Acute Heart failure Market Insight, Epidemiology And Market Forecast - 2032



Request Sample

View Pricing